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Abstract
Background: There are many studies that associate vitamin D serum levels in older persons with muscle strength,
physical performance and risk of fractures and falls. However, current evidence is insufficient to make a general
recommendation for administrating calcium and vitamin D to older persons. The objective of this study is to
determine the effectiveness of calcium and vitamin D supplementation in improving musculoskeletal function and
decreasing the number of falls in person aged over 65 years.
Methods/Design: Phase III, randomized, double blind, placebo-controlled trial to evaluate the efficacy of already
marketed drugs in a new indication. It will be performed at Primary Care doctor visits at several Healthcare Centers
in different Spanish Health Areas. A total of 704 non-institutionalized subjects aged 65 years or older will be
studied (sample size calculated for a statistical power of 80%, alpha error 0.05, annual incidence of falls 30% and
expected reduction of 30% to 20% and expected loss to follow up of 20%). The test drug containing 800 IU of
vitamin D and 1000 mg of calcium will be administered daily. The control group will receive a placebo. The
subjects will be followed up over two years. The primary variable will be the incidence of spontaneous falls. The
secondary variables will include: consequences of the falls (fractures, need for hospitalization), change in calcidiol
plasma levels and other analytical determinations (transaminases, PTH, calcium/phosphorous, albumin, creatinine,
etc.), change in bone mass by densitometry, change in muscle strength in the dominant hand and change in
musculoskeletal strength, risk factors for falls, treatment compliance, adverse effects and socio-demographic data.
Discussion: The following principles have been considered in the development of this Project: the product data
are sufficient to ensure that the risks assumed by the study participants are acceptable, the study objectives will
probably provide further knowledge on the problem studied and the available information justifies the
performance of the study and its possible risk for the participants.
If calcium and vitamin D supplementation is effective in the prevention of falls and fractures in the elderly
population, a recommendation may be issued with the aim of preventing some of the consequences of falls that
affect quality of life and the ensuing personal, health and social costs.
Trial Registration: ClinicalTrials.gov: NCT01452243
Clinical trial authorized by the Spanish Medicines Agency: EudraCT number 2006-001643-63.
Background
Vitamin D insufficiency is common in older people [1]
and is associated with several disorders related to aging
such as osteoporosis, which leads to a significantly
increased risk of bone fractures [2]. These are associated
with physical disabilities, reduced quality of life, increased
mortality and increase in healthcare costs [3]. According
to the SENECA study [4], carried out in elderly people in
11 European countries, 47% of the elderly people had
vitamin D deficiency (< 12 ng/ml). This deficiency was
more common in Mediterranean countries than in
Northern European countries, probably because in the
latter countries there is a greater consumption of fish,
fortified foods and vitamin D supplements.
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According to several authors [5-10], vitamin D serum
level is related to muscular strength, physical functional
status and risk of fractures and falls, the annual incidence
of which is around 30% in persons over 65 years [11]. It
has been demonstrated that in institutionalized women,
daily calcium and vitamin D supplementation decreases
the number of falls and risk of fracture, increases bone
mineral density and improves musculoskeletal function
[12-14]. The conclusion in a Cochrane review [15],
designed to determine the effect of vitamin D on the pre-
vention of fractures in elderly people with senile or post-
menopausal osteoporosis, is that the efficacy of this vita-
min or of its analogues in the prevention of fractures
remains unknown. A reduction in hip fractures in institu-
tionalized, frail, elderly people was observed with the
concomitant administration of calcium supplements, but
the effect in community-dwelling, younger, healthy older
adults was unknown.
According to the result of another systematic review,
there is a balance between positive and neutral results
[16]. Its use is controversial as it seems clear that is has a
positive effect on sub-clinical vitamin D deficiency, resol-
ving a sub-clinical hypovitaminosis state or osteomalacia,
but for people living at home not all studies show benefi-
cial effects on bone mass [17]. In their conclusions, the
authors of this review state that, overall the evidence ana-
lyzed is of intermediate consistency, sufficient for its indi-
vidualized use, especially in patients with calcium or
vitamin D deficiency. However, in order to be able to
issue a generalized recommendation, rigorously designed
clinical trials are needed, with a sufficient sample size,
which can be reproduced in different clinical populations
and geographical areas.
Another systematic review [18], aimed at evaluating the
effect of vitamin D on strength, physical performance and
falls in elderly people in 13 clinical trials (2496 patients),
concluded that although there is insufficient evidence that
vitamin D supplementation improves physical function in
the elderly, some data suggest a benefit of vitamin D com-
bined with calcium. Large, well-designed studies are
needed to confirm these findings.
More recently [19], in a meta-analysis performed with a
sample of 1237 patients, it was concluded that vitamin D
supplementation appears to reduce the risk of falls by
more than 20%, both in institutionalized and ambulatory
elderly people, although further studies should be consid-
ered on the effects of different types and doses of vitamin
D and the role of calcium supplements.
There is now general agreement on the importance of
vitamin D deficiency in the pathogenesis of osteoporosis
and the loss of muscle strength in elderly subjects. How-
ever questions are raised on how supplements should be
used for prevention in the future. Studies have been per-
formed in different populations with different baseline
vitamin D status and different administration regimens,
which makes it difficult to compare results [20]. According
to forecasts, the population of over 65 years in developed
countries will have doubled by 2050, therefore, this will be
the age group with the greatest risk of developing osteo-
porosis and related fractures [21].
Calcium and vitamin D are the mainstay in the treat-
ment of osteoporosis and it is accepted [22] that for
women over 65 years with a bone mineral density of -2.5,
supplementation (1200 mg of calcium and 800 U of vita-
min D) is justified. These can be taken together with other
drugs, depending on the presence of risk factors for frac-
ture, the choice of which should be individualized.
Perhaps healthcare policies need to be adopted on the
administration of vitamin D supplements in populations at
risk of osteoporosis, such as the elderly population and
post-menopausal women in Spain and other Mediterra-
nean countries [20]. Vitamin D supplementation could be
an attractive public health intervention measure; although
further studies are needed before a generalized recommen-
dation can be issued in this respect.
Study objectives
The first objective is to determine the efficacy of calcium
and vitamin D supplementation at doses of 1200 mg and
800 IU, respectively, to reduce the incidence of falls and
fractures in non-institutionalized elderly people.
The second objective is to measure and compare treat-
ment groups (calcium and vitamin D vs placebo) as
regards muscle strength and musculoskeletal function,
bone mineral density, calcidiol level and treatment safety.
Methods/design
Design
Phase III clinical trial to evaluate the efficacy and safety of
already marketed drugs in a new indication. Parallel
group, randomized, double blind, placebo controlled trial.
Study location and subjects
Patients will be recruited at primary care doctor visits. The
subsequent visits will be at the health Centers of the parti-
cipating Spanish autonomous communities: Castille-La
Mancha, Andalusia, the Balearic Islands and Catalonia.
The target population is non-institutionalized patients
of 65 years or over. The inclusion criteria are: aged over
65 years with normal renal function, normal transami-
nase levels, normal calcium blood levels, not homebound
(not immobilized) nor in socio-healthcare institutions.
The exclusion criteria are: need for medical treatment
with calcium or vitamin D, hypersensitivity to or contra-
indication for calcium or vitamin D, medical treatment
that includes calcium or vitamin D, physical disability
that impedes their collaboration, taking thiazide diuretics,
oral anticoagulants, hormone replacement therapy,
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digitalis drugs, anticonvulsants or barbiturates and having
any of the following diseases: lithiasis, renal impairment
(serum creatinine > 1.4 mg/dl), hypo or hyperthyroidism,
Paget’s disease, chronic liver disease, tumors, sarcoidosis,
impaired intestinal absorption or chronic alcoholism (>
40 g/day).
Sample size
The sample size was calculated statistically to obtain a
power of 80% with an alpha error of 0.05. In order to
demonstrate an effect in calcium and vitamin D treated
patients, consisting of a 30% to 20% reduction in the inci-
dence of falls (relative risk reduction equivalent to 33%), a
sample size of 586 (293 in the treatment group and 293 in
the non-treatment group) is needed. Assuming a 20% loss
to follow-up, 704 subjects between the two groups need to
be selected. The two groups will be of equal size in order
to obtain the greatest statistical power.
Blinding and group assignment
After determining that the patients meet the inclusion cri-
teria and do not meet the exclusion criteria, they will be
randomized and assigned to the treatment or the control
group. The randomization list will be generated by a com-
puter using pseudo-random numbers. Randomization will
be centralized. The investigators will receive the informa-
tion necessary to give each patient the corresponding
treatment in blinded conditions. To protect the blinding,
the placebo and the test treatment will look exactly the
same. The randomization list will contain a patient identi-
fication number and the number of the treatment to
which he/she has been assigned. This patient number will
be used as patient identification in all trial documentation,
including the case report form.
To ensure objectivity in measuring the results, the
study will be performed in blinded conditions for the
patients, the investigators and the data analysts who will
not know the labels of the groups they will compare.
The placebo and test treatment will have an identical
appearance and will only be identified by a code num-
ber. The assignment will be unknown by the patient and
investigator.
Intervention
The pharmacological intervention will be the daily admin-
istration of chewable tablets containing 800 IU of vitamin
D and 1200 mg of calcium. They will be administered over
2 years during the months of November to April in order
to avoid the influence of sunlight. Dose adjustment is not
contemplated during the study. Concomitant treatment
with thiazide diuretics, digitalis drugs, anticonvulsants or
barbiturates will not be permitted.
The control drug will be chewable placebo tablets with
the same appearance as the test drug.
Subject follow-up
The subjects will be followed up for a 2 year period. They
will be selected at primary care doctor visits, when they
will be asked to participate in the study. Once the patients
have given their informed consent they will be given an
appointment for the randomization visit and an appoint-
ment for the analytical tests and densitometry examination
before starting treatment.
At the randomization visit the patient will be assigned to
one of the study groups, their medical history will be
taken, they will be given a physical examination and the
study medicine will be dispensed. The following visits will
be at 3, 6, 9, 12, 15, 18, 21 and 24 months. At these visits
the efficacy (data on falls, fractures, muscle strength and
mobility and musculoskeletal function) and safety (the
detection of adverse effects) parameters will be collected,
treatment compliance will be evaluated and the medica-
tion will be dispensed.
Discontinuation of treatment will be for the following
reasons: completion of follow-up period (two consecutive
years), death, violation of protocol, adverse event, inter-
current illness causing immobilization for more than 30
days and patient abandoning trial or withdrawing
informed consent.
Definitions of the primary variables and measuring
methods
The primary variable will be the incidence of spontaneous
falls according to the FICSIT (Frailty and Injury: Coopera-
tive Study of Intervention Techniques) definition: “Unin-
tentionally coming to rest on the ground, floor, or other
lower level. Coming to rest against furniture or a wall was
not counted as a fall.” Information on the circumstances
of the fall (apparent cause, activity performed, time and
place and need of help) will be obtained by an interview.
The following are the secondary variables:
- Consequence of falls (bone fractures at any loca-
tion, need for healthcare, need for hospitalization,
bed-ridden).
- Change in calcidiol [25(OH)D3] plasma levels
(determined by RIA at baseline and at 6 and 18
months). Vitamin D deficiency is defined as a calci-
diol plasma level lower than 10 ng/ml.
- Levels of transaminases, parathyroid hormone
(PTH), calcium, phosphorous and serum creatinine,
determined by tests on venous blood samples
obtained in a fasted state. Calcium/creatinine index,
determined by analysis of second morning urine.
- Change in bone mass (bone density or mineral con-
tent) obtained by densitometry (risk of fracture).
Osteoporosis will be diagnosed based on a densitome-
try T-score of less than 2.5 in the vertebral column,
according to WHO criteria.
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- Change in muscle strength in the dominant hand.
Determined by dyanometry (with a mean of 3 attempts
to obtain a muscle strength measurement).
- Changes in musculoskeletal function, determined by
the timed up and go test (the elderly person gets up
from a chair with arms, walks three meters, turns
round, walks back and sits down again). Taking more
than 20 seconds indicates a high risk for falls.
- Stratification and potentially confounding variables;
gender, age and other demographic data (social class,
education level, marital status).
- Risk factors for falls: taking pre-disposing medication,
health problems, toxic habits, physical exercise, living
arrangements, sight or hearing difficulties, functional
status (Katz index).
- Treatment compliance. To determine this, the
patient will bring the medication containers (empty
or partially empty) to each visit. According to their
degree of compliance (difference between number of
tablets dispensed and number of tablets consumed)
the patients will be classified as normal compliers
(89-100%), hypercompliers (> 110%) or hypocom-
pliers (< 80%). Compliance will also be evaluated by
the Morisky-Green test.
- Serious adverse events or any other adverse event.
An adverse event is considered as any untoward medi-
cal occurrence in any patient included in the study
which does not necessarily have a causal relationship
with the treatment. An adverse event can therefore be
any unfavorable and unintended sign (including an
abnormal laboratory finding), symptom, or disease
temporally associated with the use of a medicinal pro-
duct. Known adverse events of the calcium vitamin D
combination at the proposed doses are: occasionally
slight gastrointestinal alterations and the possibility of
stimulating kidney stone formation in patients with
impaired renal function.
Statistical analysis
After performing data cleaning and imputation, explora-
tory analysis and categorization or transformation of
variables the following analyses will be performed:
- Comparison of the variables of interest and the stra-
tification and potentially confounding variables in the
treated and non treated groups at the start of the
study. We will determine if, despite using randomized
assignment, the two groups are homogenous.
- A first raw analysis will be performed to calculate
the following parameters and their confidence inter-
vals: ARR (absolute risk reduction), RRR (relative risk
reduction) and NNT (number necessary to treat). A
stratified analysis will also be performed adjusting for
each independent variable. If there are differences
between the raw RR and the adjusted RR, the homo-
geneity between the categories will be determined to
establish if the variable is effect modifying or con-
founding. The incidence of the variables in each
group will be described and compared (comparison
of proportions by the chi-squared test).
- A survival (fall-free period) analysis will be per-
formed in both study groups (Kaplan-Meier and Log
Rank test). Then the effect of treatment on the risk
of falls will be determined by constructing a Cox
proportional hazards model.
- The effect of treatment on calcium and vitamin D
levels will be estimated adjusted for changes in treat-
ment compliance (generalized linear models for
repeated measures).
Data will be analyzed on an intention to treat basis
including all randomized patients in the efficacy and safety
analyses according to their randomized treatment group
regardless of the treatment received. A per protocol analy-
sis will also be performed for the primary variables. This
will exclude patients who did not meet any of the selection
criteria and did not comply with treatment.
For ethical reasons an intermediate analysis will be
performed to decide if the study should be discontinued
prematurely because of frequent adverse effects occur or
an obvious improvement in the test group.
Discussion
If calcium and vitamin D supplementation is effective in
the prevention of falls and fractures in the elderly popula-
tion, a recommendation may be issued with the aim of
preventing some of the consequences of falls that affect
quality of life and the ensuing personal, health and social
costs.
Using a randomization procedure will reduce selection
bias as the investigator does not assign the treatment and
any factor affecting participation will be equally divided
between the two groups. Confounding is also reduced
because randomization tends to share the determining
factors that may affect the final result equally among the
groups.
However, bias in the collection of information could
occur in the study, such as patient evolution, determined
by the aging process throughout the two study years, also
the regression toward the mean or tendency of the con-
tinuous variables to approach the mean value in succes-
sive measurements. In our case this is applicable to the
number of falls by the elderly people or the analytical test
results. Furthermore, the participants, who are aware of
the study objectives, could contribute to what is termed
“hypothesis guessing” and try to downplay the impor-
tance of falls without consequences. There will also be a
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possible risk of differential loss to follow up between the
groups being compared, due to the duration of the study
and the placebo effect, which could contribute to patients
abandoning the study because they consider the medica-
tion they are given is having no effect.
Follow-up visits with controls every 3 months will
allow us to balance recommendations on treatment
compliance and increase the possibility of detecting
adverse effects. This will give us greater control over the
development of the study.
As regards problems of external validity, the partici-
pants may not represent all eligible subjects if the rate of
non responders were high. Furthermore, the study popu-
lation characteristics (socio-economic level, life-style,
etc.) may mean that the results cannot be directly trans-
ferred to any other population.
This is a multi-centre study therefore possible sources of
error could be: deviation from or misinterpretation of the
protocol, obtaining inaccurate or incomplete data and data
errors or omissions. To avoid these errors the study per-
sonnel will be trained and certified, we will have appropri-
ate documentation, high quality data collection protocols
and a data processing system with editing techniques to
identify anomalous or erroneous data. To prevent any
intentional fraud there will be periodical inspection visits
to the participating Centers.
The study protocol has been evaluated and approved by
the Investigational Review Board/Independent Ethics
Committee of the Albacete Health Area. The following
ethical principles will be respected throughout the study:
consent to voluntarily participate, guarantee of anonymity
of the information provided by the patient, and restriction
of the data provided by the interviewee to the proposed
investigation. The investigators will ensure that the study
will be performed in full compliance with the Declaration
of Helsinki in accordance with current legislation (Royal
Decree 223/2004) and the New Code of Medical Ethics,
approved by the Spanish Medical Association. The study
will fully adhere to Good Clinical Practice standards and a
civil liability insurance will be taken out to cover any pos-
sible harm and injury.
The investigators will be responsible for obtaining writ-
ten informed consent from the participants once they
have adequately explained the objectives, methods,
expected benefits and potential risks. The subjects will be
informed that they are free to refuse to participate or to
withdraw from the study at any time and for any reason.
The following principles have been considered in the
development of this Project: the product data are suffi-
cient to ensure that the risks assumed by the study parti-
cipants are acceptable, the study objectives will probably
provide further knowledge on the problem studied and
the available information justifies the performance of the
study and its possible risk for the participants.
Finally, the study results may only be published in
scientific journals or presented at scientific meetings,
according to the quality criteria recommended by the
CONSORT statement.
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